Xspray Pharma 관리

관리 기준 확인 2/4

Xspray Pharma CEO는 Per Andersson, Jan2006 에 임명되었습니다 의 임기는 18.75 년입니다. 총 연간 보상은 SEK 3.74M, 70.5% 로 구성됩니다. 70.5% 급여 및 29.5% 보너스(회사 주식 및 옵션 포함). 는 SEK 9.38M 가치에 해당하는 회사 주식의 0.57% 직접 소유합니다. 9.38M. 경영진과 이사회의 평균 재임 기간은 각각 0.9 년과 5.4 년입니다.

주요 정보

Per Andersson

최고 경영자

SEK 3.7m

총 보상

CEO 급여 비율	70.5%
CEO 임기	18.8yrs
CEO 소유권	0.6%
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	5.4yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Per Andersson 의 보수는 Xspray Pharma 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-SEK 215m
Mar 31 2024	n/a	n/a	-SEK 213m
Dec 31 2023	SEK 4m	SEK 3m	-SEK 180m
Sep 30 2023	n/a	n/a	-SEK 180m
Jun 30 2023	n/a	n/a	-SEK 170m
Mar 31 2023	n/a	n/a	-SEK 148m
Dec 31 2022	SEK 4m	SEK 2m	-SEK 132m
Sep 30 2022	n/a	n/a	-SEK 128m
Jun 30 2022	n/a	n/a	-SEK 114m
Mar 31 2022	n/a	n/a	-SEK 102m
Dec 31 2021	SEK 3m	SEK 2m	-SEK 97m
Sep 30 2021	n/a	n/a	-SEK 60m
Jun 30 2021	n/a	n/a	-SEK 57m
Mar 31 2021	n/a	n/a	-SEK 56m
Dec 31 2020	SEK 3m	SEK 2m	-SEK 52m
Sep 30 2020	n/a	n/a	-SEK 56m
Jun 30 2020	n/a	n/a	-SEK 55m
Mar 31 2020	n/a	n/a	-SEK 49m
Dec 31 2019	SEK 3m	SEK 2m	-SEK 46m
Sep 30 2019	n/a	n/a	-SEK 41m
Jun 30 2019	n/a	n/a	-SEK 34m
Mar 31 2019	n/a	n/a	-SEK 30m
Dec 31 2018	SEK 2m	SEK 2m	-SEK 23m
Sep 30 2018	n/a	n/a	-SEK 17m
Jun 30 2018	n/a	n/a	-SEK 16m
Mar 31 2018	n/a	n/a	-SEK 8m
Dec 31 2017	SEK 2m	SEK 1m	-SEK 14m

보상 대 시장: Per 의 총 보상 ($USD 360.81K ) UK 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 734.17K ).

보상과 수익: 회사가 수익성이 없는 동안 Per 의 보상이 증가했습니다.

CEO

Per Andersson (57 yo)

18.8yrs

테뉴어

SEK 3,743,000

보상

Dr. Per Andersson Ph.D. has been the Chief Executive Officer of Xspray Pharma AB (publ) since 2006. Dr. Andersson serves as the Chief Executive Officer of Xspray Microparticles AB. Dr. Andersson joined XSp...

리더십 팀

이름	위치	테뉴어	보상	소유권
Per Andersson	Chief Executive Officer	18.8yrs	SEK 3.74m	0.57% SEK 9.4m
Mustafa Demirbüker	Co-Founder and Science Director	no data	데이터 없음	데이터 없음
Niklas Adenborg	Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Linda Glimberg	Chief Operating Officer	less than a year	데이터 없음	0.0053% SEK 87.0k
Kerstin Hasselgren	Senior Advisor & Head of IR	less than a year	데이터 없음	0.024% SEK 398.8k
Charlotta Liljebris	Senior Vice President of Research & Development	6.8yrs	데이터 없음	0.0089% SEK 145.1k
Edward Jordan	Chief Commercial Officer	1.1yrs	데이터 없음	데이터 없음
Anette Abrahamsson	Senior Vice President of Regulatory Affairs	less than a year	데이터 없음	0.0044% SEK 72.5k
Christer Hallgren	Senior Vice President of Intellectual Property	6.8yrs	데이터 없음	0.089% SEK 1.5m

0.9yrs

평균 재임 기간

56.5yo

평균 연령

경험이 풍부한 관리: 0GHZ 의 관리팀은 경험 (평균 재직 기간 0.9 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Maris Hartmanis	Independent Director	9.8yrs	SEK 323.00k	0.092% SEK 1.5m
Carl-Johan Spak	Independent Director	9.8yrs	SEK 270.00k	데이터 없음
Anders Ekblom	Chairman	3.4yrs	SEK 510.00k	1.71% SEK 27.9m
Torbjörn Koivisto	Independent Director	7.8yrs	SEK 253.00k	데이터 없음
Christine Lind	Independent Director	5.4yrs	SEK 270.00k	데이터 없음
Anders Bladh	Director	3.4yrs	SEK 253.00k	2.49% SEK 40.7m
Robert Molander	Independent Director	2.4yrs	SEK 218.00k	0.030% SEK 483.5k

5.4yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: 0GHZ 의 이사회는 경험(평균 재직 기간 5.4 년)으로 간주됩니다.

Xspray Pharma 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Xspray Pharma AB (publ), Annual General Meeting, May 13, 2025

Xspray Pharma AB's Nomination Committee for the Annual General Meeting 2025

Director recently bought kr4.8m worth of stock

Director recently bought kr143k worth of stock

Insufficient new directors

Insufficient new directors

Recent updates

Xspray Pharma AB (publ) to Report Fiscal Year 2024 Final Results on Mar 27, 2025

Xspray Pharma AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 135.04904 million.

Xspray Pharma AB (publ), Annual General Meeting, May 13, 2025

Xspray Pharma AB's Nomination Committee for the Annual General Meeting 2025

Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission

Director recently bought kr4.8m worth of stock

Director recently bought kr143k worth of stock

Insufficient new directors

Xspray Pharma Ab's Xs003 Study Shows Matching Bioavailability to Tasigna At More Than A 50% Lower Dose

Insufficient new directors

Xspray Pharma AB (publ) Announces to Present Data At ASCO Highlighting Frequent Decideication of PPIs with TKIs in CML-Patients and Greater Than Expected Positive Effects on the Bioavailability of Crystalline Dasatinib

Xspray Pharma AB (publ) to Report Fiscal Year 2024 Results on Feb 12, 2025

Xspray Pharma AB (publ) to Report Q2, 2024 Results on Aug 07, 2024

FDA Accepts Xpray Pharma's NDA-Resubmission for Dasynoc® - PDUFA

Xspray Pharma AB (Publ) Announces CFO Changes

Director recently bought kr2.1m worth of stock

Director recently bought kr395k worth of stock

Xspray Pharma Ab's Xs003 Achieves Superior Bioavailability Milestone, Matching TASIGNA At Reduced Dosage

Director recently bought kr5.0m worth of stock

New minor risk - Shareholder dilution

Xspray Pharma AB Through HyNap™ technology Announces Results from Drug Interaction Studies

Forecast to breakeven in 2024

Xspray Pharma AB (publ), Annual General Meeting, May 21, 2024

New major risk - Financial position

Xspray Pharma Appoints Edward P. Jordan as Chief Commercial Officer

Xspray Pharma and Bristol Myers Squibb Reach Settlement on Dasynoc Patent Litigation, Paving Way for Early Market Launch

Forecast to breakeven in 2024

Xspray Pharma AB (publ) to Report Q4, 2023 Results on Feb 14, 2024

Xspray Pharma AB (publ) Receives Request for Additional Information Concerning Dasynoc from FDA

Forecast to breakeven in 2024

Xspray Pharma AB (publ) to Report Q3, 2023 Results on Nov 08, 2023

Forecast to breakeven in 2024

Director recently bought kr2.6m worth of stock

Xspray Pharma AB (publ)'s Drug Candidate Xs004 Granted Orphan Drug Designation in the US for the Treatment of Acute Lymphoblastic Leukemia

Forecast to breakeven in 2024

Xspray Pharma AB (publ), Annual General Meeting, May 16, 2023

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Xspray Pharma AB Appoints Thomas Walz to the Newly Established Position Chief Medical Officer

Xspray Pharma AB (publ) Approves Election of Robert Molander as Member of its Board of Directors

Forecast to breakeven in 2024

Xspray Pharma AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

Xspray Pharma AB (publ), Annual General Meeting, May 19, 2022

Xspray Pharma AB (Publ) Appoints Anna-Karin as Global Head of Marketing and Sales, Effective March 15, 2022

Xspray Pharma AB (Publ) Announces Fda Allows Review of Application for Market Approval for Dasynoc™

Forecast breakeven date pushed back to 2024

No longer forecast to breakeven

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령